These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9069682)

  • 61. Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy.
    Pillai K; Kraya N
    Aust N Z J Psychiatry; 2000 Feb; 34(1):160-3. PubMed ID: 11185930
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A study of compliance with FDA recommendations for pemoline (Cylert).
    Willy ME; Manda B; Shatin D; Drinkard CR; Graham DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):785-90. PubMed ID: 12108802
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatotoxicity due to pemoline (Cylert): a report of two cases.
    Pratt DS; Dubois RS
    J Pediatr Gastroenterol Nutr; 1990 Feb; 10(2):239-41. PubMed ID: 2303976
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect on growth in pemoline-treated children with attention deficit disorder.
    Friedmann N; Thomas J; Carr R; Elders J; Ringdahl I; Roche A
    Am J Dis Child; 1981 Apr; 135(4):329-32. PubMed ID: 7211792
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pemoline hepatotoxicity and postmarketing surveillance.
    Safer DJ; Zito JM; Gardner JE
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):622-9. PubMed ID: 11392339
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Attention deficit hyperactivity disorder: does it affect adults too?
    Heath CT; Wright HH; Batey SR
    South Med J; 1990 Dec; 83(12):1396-401. PubMed ID: 2251528
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pemoline in attention deficit disorder and alcoholism: a case study.
    Turnquist K; Frances R; Rosenfeld W; Mobarak A
    Am J Psychiatry; 1983 May; 140(5):622-4. PubMed ID: 6303137
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Oral pemoline kinetics in hyperactive children.
    Sallee F; Stiller R; Perel J; Bates T
    Clin Pharmacol Ther; 1985 Jun; 37(6):606-9. PubMed ID: 4006361
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pemoline and hepatotoxicity.
    McCurry L; Cronquist S
    Am J Psychiatry; 1997 May; 154(5):713-4. PubMed ID: 9137138
    [No Abstract]   [Full Text] [Related]  

  • 70. Gilles de la Tourette's disorder associated with pemoline.
    Mitchell E; Matthews KL
    Am J Psychiatry; 1980 Dec; 137(12):1618-9. PubMed ID: 6933864
    [No Abstract]   [Full Text] [Related]  

  • 71. EEG and clinical findings during pemoline treatment in children and adults with attention deficit disorder. An 8-week open trial.
    Caresia L; Pugnetti L; Besana R; Barteselli F; Guareschi Cazzullo A; Musetti L; Scarone S
    Neuropsychobiology; 1984; 11(3):158-67. PubMed ID: 6472603
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey.
    Langer DH; Sweeney KP; Bartenbach DE; Davis PM; Menander KB
    Drug Alcohol Depend; 1986 Jun; 17(2-3):213-27. PubMed ID: 3743405
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Substituting stimulants in treating behavior disorders.
    El-Defrawi MH; Greenhill LL
    Am J Psychiatry; 1984 Apr; 141(4):610. PubMed ID: 6703148
    [No Abstract]   [Full Text] [Related]  

  • 74. Severe hypotension in a patient receiving pemoline during general anesthesia.
    Bohringer CH; Jahr JS; Rowell S; Mayer K
    Anesth Analg; 2000 Nov; 91(5):1131-3. PubMed ID: 11049895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pemoline (Cylert)-induced hepatotoxicity.
    Elitsur Y
    J Pediatr Gastroenterol Nutr; 1990 Jul; 11(1):143-4. PubMed ID: 2388127
    [No Abstract]   [Full Text] [Related]  

  • 76. Pemoline, depressive symptoms, and escape from dexamethasone suppression.
    Farmer P; Unis AS; Hsu G
    J Clin Psychopharmacol; 1983 Oct; 3(5):331-2. PubMed ID: 6630594
    [No Abstract]   [Full Text] [Related]  

  • 77. Sleep practitioners need to be aware of new changes in the labeling of pemoline (CYLERT).
    Littner M
    Sleep; 1999 Nov; 22(7):833. PubMed ID: 10566901
    [No Abstract]   [Full Text] [Related]  

  • 78. 2001 American Academy of Pediatrics practice parameter on attention-deficit/hyperactivity disorder.
    Yusin AS
    Pediatrics; 2004 Feb; 113(2):428-9; discussion 428-9. PubMed ID: 14754970
    [No Abstract]   [Full Text] [Related]  

  • 79. Treatment of chronic cocaine abuse and attention deficit disorder, residual type, with magnesium pemoline.
    Weiss RD; Pope HG; Mirin SM
    Drug Alcohol Depend; 1985 May; 15(1-2):69-72. PubMed ID: 4017880
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Delusional parasitosis associated with pemoline.
    Krauseneck T; Soyka M
    Psychopathology; 2005; 38(2):103-4. PubMed ID: 15855835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.